Olmesartan medoxomil: recent clinical and experimental acquisitions. - Wikidata - awgldk - TriplyDB

Olmesartan medoxomil: recent clinical and experimental acquisitions.

Olmesartan medoxomil: recent clinical and experimental acquisitions.

http://www.wikidata.org/entity/Q37581623

about

Olmesartan vs. ramipril in elderly hypertensive patients: review of data from two published randomized, double-blind studies.Transdermal delivery of angiotensin II receptor blockers (ARBs), angiotensin-converting enzyme inhibitors (ACEIs) and others for management of hypertension.Antihypertensive efficacy of olmesartan medoxomil and ramipril in elderly patients with mild to moderate hypertension grouped according to renal function status : a retrospective analysis.Inhibitory effects of ketoconazole and rifampin on OAT1 and OATP1B1 transport activities: considerations on drug-drug interactions.Antihypertensive efficacy and safety of olmesartan and ramipril in elderly patients with mild to moderate systolic and diastolic essential hypertension

P2860

Q35085669-76D91C7A-1125-4DC9-B2B4-2F68F7130522 Q38234364-37F9892A-D7FD-4A75-AC95-9DDD45455211 Q42688526-C558FAC4-E348-4AE5-8005-8A77E1698D66 Q48677705-7A310C6C-E6BD-4614-B10C-BBE4F561D2DD Q57490186-ED38978A-6EEC-4CB3-A7CF-B4BA973B11E4

P2860

Olmesartan medoxomil: recent clinical and experimental acquisitions.

http://www.wikidata.org/entity/Q37581623

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on September 2009

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Olmesartan medoxomil: recent clinical and experimental acquisitions.

@en

Olmesartan medoxomil: recent clinical and experimental acquisitions.

@nl

type

label

Olmesartan medoxomil: recent clinical and experimental acquisitions.

@en

Olmesartan medoxomil: recent clinical and experimental acquisitions.

@nl

prefLabel

Olmesartan medoxomil: recent clinical and experimental acquisitions.

@en

Olmesartan medoxomil: recent clinical and experimental acquisitions.

@nl

P1433

Q37581623-A9616ED0-0E8B-487B-A7F1-CBFAA9A46FF8

P1476

Q37581623-2E15D6E1-E349-4A25-9E4D-81C3DE54E9EF

P2093

Q37581623-1EEFAB43-F929-4452-8809-1900B2E9AF77

Q37581623-2540AF38-5EB1-4C08-BAEF-EE125A31C554

Q37581623-28E51AC2-8F46-4A73-BAC2-B4E6F616E965

Q37581623-3A969020-9382-4525-8096-AEDB5F2764DF

Q37581623-AF29B88E-5EBD-4E80-9B01-E1522853E250

Q37581623-C4899BE2-3324-4462-AE19-C72EFFE0D309

P2860

Q37581623-0347FD58-506F-4E69-9729-42DB24E809F4

Q37581623-16F88E43-7747-4DAB-8DB9-019B0C526143

Q37581623-175540B2-101A-4A4E-9235-60E11E0E50E9

Q37581623-2590AFFE-79DE-404B-AB4E-3316AD63A342

Q37581623-3C59C111-B7D5-49B4-BDF9-FB11ECBDC289

Q37581623-442C14AD-01F3-435F-813C-3706249FF0CC

Q37581623-50D75E61-6A11-4236-A025-D2D6DBB1E629

Q37581623-675CC4F0-9C0C-4A8B-9E1B-BC129533093A

Q37581623-6EB8199A-47F5-43BC-B44F-1A02E9478B12

Q37581623-78B22CD6-D96F-4ECC-BD97-90AC8C790285

P304

Q37581623-A92FA6A7-CC66-46D2-8705-2819E26BADDF

P31

Q37581623-DB763163-CD28-4E4C-A554-AC9B93CDD391

P356

Q37581623-641D79A0-2F16-4872-A876-D8F88031584C

P407

Q37581623-8CAE0B36-30A1-48F5-8D2C-C9D72C4A29BD

P433

Q37581623-400E5338-AFFC-4203-89BC-55165F79A0F7

P478

Q37581623-E9C08C0B-FF94-4A52-985C-A388EAABBE97

P577

Q37581623-979B2B74-5377-4099-A34E-F05D3A015BB2

P698

Q37581623-3067731B-91A8-403D-9AD2-F92E123CB998

P356

17425250903203811

P1433

Expert Opinion on Drug Metabolism & Toxicology

P1476

Olmesartan medoxomil: recent clinical and experimental acquisitions.

@en

P2093

Alessandra Rossi Ricci

http://www.w3.org/2001/XMLSchema#string

Antonio D'Ospina

http://www.w3.org/2001/XMLSchema#string

Francesca Cagnoni

http://www.w3.org/2001/XMLSchema#string

Maurizio Destro

http://www.w3.org/2001/XMLSchema#string

Ngu Njwe Christian Achiri

http://www.w3.org/2001/XMLSchema#string

Paola Preti

http://www.w3.org/2001/XMLSchema#string

P2860

The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes

Angiotensin II receptor antagonists.

Clinical studies of CS-866, the newest angiotensin II receptor antagonist.

Cough and angioneurotic edema associated with angiotensin-converting enzyme inhibitor therapy. A review of the literature and pathophysiology.

Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol.

Can the pharmacokinetic characteristics of olmesartan medoxomil contribute to the improvement of blood pressure control?

Clinical efficacy and tolerability of olmesartan.

The cardiovascular disease continuum validated: clinical evidence of improved patient outcomes: part I: Pathophysiology and clinical trial evidence (risk factors through stable coronary artery disease).

Molecular characterisation of the interactions between olmesartan and telmisartan and the human angiotensin II AT1 receptor.

Rationale, design and patient baseline characteristics of OlmeSartan and calcium antagonists randomized (OSCAR) study: a study comparing the incidence of cardiovascular events between high-dose angiotensin II receptor blocker (ARB) monotherapy and c

P304

1149-1157

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1517/17425250903203811

http://www.w3.org/2001/XMLSchema#string

P407

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

5

http://www.w3.org/2001/XMLSchema#string

P577

2009-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

19689219

http://www.w3.org/2001/XMLSchema#string